BusinessAdaptimmune Announces Two Manufacturing Achievements on Its way to Become the First Fully Integrated TCR T-cell Therapy CompanyBy Nasdaq OMXJan 8, 2018, 1:00 PM UTC
BusinessAdaptimmune Announces Positive Safety Data from Pilot Studies with MAGE-A10 SPEAR T-cells and First Patient to Receive 1 billion Target Cell DoseBy Nasdaq OMXJan 8, 2018, 1:00 PM UTC
BusinessMesoblast Receives FDA Regenerative Medicine Advanced Therapy Designation for Its Cell Therapy in Heart Failure Patients With Left Ventricular Assist DevicesBy Nasdaq OMXDec 21, 2017, 11:00 AM UTC
BusinessQ Therapeutics Announces Research Collaboration With REPROCELLBy Nasdaq OMXDec 13, 2017, 12:00 PM UTC
BusinessTeneoBio’s Next Gen Multivalent anti-BCMAxCD3, TNB-383B, and Anti-BCMA UniDabs for CAR T-Cell Therapy of Multiple Myeloma Highlighted at the American Society of HematologyBy Nasdaq OMXDec 11, 2017, 1:00 PM UTC
BusinessTitle21 Health Solutions® to Showcase its BMT Software Solution 8.5 at the 2018 BMT Tandem MeetingBy Nasdaq OMXNov 30, 2017, 5:00 PM UTC
BusinessTitle21 Health Solutions® Announces ISBT 128 Compliance Service, Title21 Compliance Care™By Nasdaq OMXNov 29, 2017, 4:00 PM UTC
BusinessTeneobio and Poseida Announce License Agreement for the Use of UniDab™ in CAR T-Cell TherapyBy Nasdaq OMXMay 22, 2017, 12:02 PM UTC
